28 research outputs found

    Evaluation of the viricidal efficacy of commercially used disinfectants against Newcastle disease virus

    No full text
    The aim of this study was to evaluate the viricidal action of fourteen commonly used and commercially available disinfectants on poultry farms and are belonging to different groups of biocides against Velogenic Newcastle disease virus (NDV). Evaluation was carried on two different surfaces (cement and rubber) contaminated experimentally with Newcastle disease virus. Reliable disinfectants should pass the test if at least 2.8 log reductions were achieved, and no recoverable viruses were isolated after the treatment, the last point is very important in the evaluation as although the direct reduction in virus titer is critically needed in terminal disinfection, the recovered virus after disinfection or shed virus after vaccination will be always capable of introducing infections. Our results revealed that three disinfectants out of fourteen were able to achieve the previous test criteria 1. Calcium hypochlorite (5.5 log reduction on cement coupons, and 4.38 on rubber coupons) 2. Halamid Âź (5.5 log reduction on cement coupons, and 4.38 on rubber coupons) and 3. ZixVirox Âź (5.5 log reduction on cement coupons, and 4.38 on rubber coupons) while Virkon S Âź , PIQuat 20 Âź , Synergize Âź +Formalin, and GroundZero Âź had only achieved the required log reduction on both surfaces but failed to stop viral propagation, it’s also worth to mention that disinfectants Aquazix E52 Âź and FumagriEffisafe Âź achieved the required log reduction on cement surface only but also failed to stop viral replication, disinfectants Synergize Âź , Formic, and Citric acid neither achieved the required log reduction on both surfaces, nor stopped the virus propagation after treatment. © 2017 @ author (s)

    Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells

    Full text link
    The microenvironment of cancer cells is receiving increasing attention as an important factor influencing the progression and prognosis of tumor diseases. In multiple myeloma (MM), a hematological cancer of plasma cells, mesenchymal stem cells (MSCs) represent an integral part of the bone marrow niche and tumor microenvironment. It has been described that MM cells alter MSCs in a way that MM-associated MSCs promote the proliferation and survival of MM cells. Yet, our understanding of the molecular mechanisms governing the interaction between MM cells and MSCs and whether this can be targeted for therapeutic interventions is limited. To identify potential molecular targets, we examined MSCs by RNA sequencing and Western blot analysis. We report that MSCs from MM patients with active disease (MM-Act-MSCs) show a distinct gene expression profile as compared with MSCs from patients with other (non-) malignant diseases (CTR-MSCs). Of note, we detected a significant enrichment of the PI3K–AKT–mTOR hallmark gene set in MM-Act-MSCs and further confirmed the increased levels of related proteins in these MSCs. Pictilisib, a pan-PI3K inhibitor, selectively reduced the proliferation of MM-Act-MSCs as compared with CTR-MSCs. Furthermore, pictilisib treatment impaired the MM-promoting function of MM-Act-MSCs. Our data thus provide a deeper insight into the molecular signature and function of MSCs associated with MM and show that targeting PI3K–AKT–mTOR signaling in MSCs may represent an additional therapeutic pathway in the treatment of MM patients
    corecore